Due to its ability to act as a molecular chaperone that can stabilize many onco-proteins, HSP90 has been reported as a druggable target in many cancers, including ALK-rearranged NSCLC, HER2-amplified breast cancer and some hematological malignancies (e.g., multiple myeloma). Here, HSP90AA1 is linked to cancer.